Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors

NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
March 31, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update

-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected...
March 01, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference

NAARDEN, the Netherlands and MIAMI, March 01, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
February 09, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference

NAARDEN, the Netherlands and MIAMI, Feb. 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
January 17, 2023 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy

-- Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) ---- Median percent change in LDL-C of -59% in combination arm compared to -6% in placebo arm ----...
December 19, 2022 16:01 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer

NAARDEN, the Netherlands and MIAMI, Dec. 19, 2022 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the...
November 23, 2022 08:00 ET | Source: NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients

-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on...